Hormel Foods news

Mixed results: pricing actions improved margins and EPS, but caused volume contraction and 24.1% stock decline over three months. Company is adapting to value-conscious consumers, indicating both challenges and management response. Hold rating reflects balanced outlook.

Stock declined 10% due to revenue miss ($2.96B vs. $3.05B expected), full-year sales guidance reduction, 7% drop in sales volume, and weak consumer environment. Despite beating EPS estimates, the top-line miss and reduced outlook drove significant investor sell-off. The company's stock has eroded over recent years, leaving investors in an unforgiving mood.

While EPS beat consensus and margins expanded, net sales missed expectations and declined 2.4% YoY. Volume declined significantly across all segments (7.4% total, 9.1% retail). The company lowered full-year sales guidance and the stock is rated Zacks Rank #4 (Sell), having declined 7.3% over the past month. The Brazil divestiture and challenging external environment indicate headwinds ahead.

Hormel missed revenue expectations by 2.81% ($2.96B vs $3.05B consensus), with significant year-over-year declines in retail (-4.3%) and international (-4.7%) segments. The company also reported a substantial loss in international segment profit (-$29.23M vs +$23.41M expected). The stock has underperformed the market by 11.8 percentage points over the past month and carries a Zacks Rank #4 (Sell) rating.

Company delivered better-than-expected Q2 earnings with 14% adjusted EPS growth, positive organic sales growth across all three segments (Retail +1%, Foodservice +7%, International +5%), and evidence that the Transform & Modernize initiative is generating real cost savings. The previously problematic Jennie-O turkey business showed improvement. However, sentiment is cautiously positive rather than strongly positive due to ongoing challenges with retail volume declines, logistics costs, and consumer spending pressures, plus questions about sustainability of the turnaround.

Strong Q2 results with 3% organic sales growth and 14% adjusted EPS growth, sixth consecutive quarter of organic growth, margin expansion despite cost headwinds, and reasonable valuation at 11x EBITDA and 16x forward earnings support positive sentiment. However, dividend sustainability concerns temper the outlook.

The company's declaration of its 392nd consecutive quarterly dividend demonstrates financial stability, strong cash flow generation, and a long-standing commitment to shareholders. Membership in the S&P 500 Dividend Aristocrats further reinforces its reliability as a dividend-paying company with consistent growth over time.

Trading at 15x earnings, which is at value levels but above its typical 25x valuation when fully valued. While positioned to advance, it lacks the valuation discount and near-term catalysts that make Smithfield more attractive for outperformance.

Mixed results with EPS beat offset by sales miss. Retail segment weakness (-6% volume) contrasts with strong foodservice (+7% sales) and international (+8% sales) performance. Stock fell 0.43% on the news. Reaffirmed guidance suggests management confidence despite near-term headwinds. Strategic asset sale indicates portfolio optimization but also signals exit from less profitable segments.

Trading at historically attractive valuation with 4.7% yield above market average. Company shows turnaround promise with six consecutive quarters of organic sales growth. P/S and P/B ratios below five-year averages indicate undervaluation. Protein trend provides tailwind.

Dividend King with 60 consecutive years of annual increases, currently experiencing a turnaround with organic growth accelerating for six consecutive quarters, earnings rebounding, and company continuing dividend increases despite recent challenges.

Mentioned as a comparable example of a foundation-backed company with reliable dividend payments (Dividend King status). Used as a reference point for how Berkshire could operate in the future, but no direct impact or recommendation is made.

Used as a comparative example of how foundations use dividends to support philanthropic goals, but no direct sentiment regarding Hormel's business is expressed.

Trading at 15.5x earnings versus 10-year average of 19x, representing significant rerating opportunity. 25+ consecutive years of dividend increases with 4.82% yield. Fifth consecutive quarter of organic growth with fully covered dividend despite ongoing restructuring.

Mentioned only as a well-capitalized competitor in the alt-meat sector with no specific performance data or analysis provided in the article.

Up 13% after earnings report, reflecting positive consumer demand and company performance.

Dividend King with 60 years of increases and 5.9% yield, but facing operational challenges. Payout ratio of 131% (12-month) is concerning despite Transform & Modernize initiative showing early stabilization signs. Execution risk is central.

Down 60% from 2022 high but showing early signs of recovery with organic growth trending higher. Well-positioned in protein-focused food market aligned with GLP-1 drug trends. Dividend King status with 50+ years of increases. Unique advantage: Hormel Foundation controls 46% of shares, enabling long-term decision-making independent of Wall Street pressure.

A Dividend King showing early signs of turnaround success with rising organic growth for over a year. Well-positioned with protein focus aligned to consumer trends, and benefits from long-term thinking due to Hormel Foundation's 47% ownership, reducing pressure from short-term investors.

Offers both branded pricing power and private-label manufacturing exposure. Dividend King with 60 consecutive years of dividend increases, providing stability through economic cycles.

Five consecutive quarters of organic sales growth, strategic portfolio shift toward value-added products, new CEO leadership, and expected adjusted earnings growth of 4-10% in fiscal 2026. Well-positioned for GLP-1 drug-driven consumption changes. Dividend King status with 5% yield.

Trading at historically high dividend yield (5.2%) with price-to-sales and price-to-book ratios below 5-year averages. Dividend King status with 60+ years of consecutive dividend increases demonstrates resilience. Protein-focused portfolio aligns well with GLP-1 drug trends. Currently undervalued despite near-term earnings pressure.

Hormel is a Dividend King with 59 consecutive years of dividend increases and a high yield of 4.69%. It has historically outperformed the S&P 500 during downturns and analysts project 12% upside with a median price target of $27.50. The company's consumer staples products are recession-resistant.